For the quarter ending 2026-03-31, ALMR had $34,584K increase in cash & cash equivalents over the period. -$20,947K in free cash flow.
| Cash Flow | 2026-03-31 |
|---|---|
| Net loss | -21,325 |
| Depreciation and amortization expense | 1,167 |
| Stock-based compensation | 1,467 |
| Loss on remeasurement of convertible notes | 8,594 |
| Convertible note issuance costs included in net income | 361 |
| Unrealized foreign exchange loss (gain) | -165 |
| Non-cash operating lease costs | 461 |
| Amortization of debt issuance costs | 67 |
| Change in fair value of warrant liabilities | 84 |
| Accounts receivable | 6,854 |
| Inventory | 1,265 |
| Prepaid expenses and other current assets | 1,960 |
| Other noncurrent assets | 327 |
| Accounts payable | 1,339 |
| Operating lease liabilities | -1,087 |
| Accrued expenses and other liabilities | -1,234 |
| Net cash used in operating activities | -20,347 |
| Purchases of property and equipment | 600 |
| Capitalized software development costs | 178 |
| Net cash (used in) provided by investing activities | -778 |
| Proceeds from issuance of convertible notes | 56,500 |
| Payment of third-party debt issuance costs | 324 |
| Proceeds from issuance of common stock upon exercise of stock options | 1,803 |
| Payment of deferred offering costs | 2,218 |
| Net cash provided by financing activities | 55,761 |
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash | -52 |
| Net increase in cash, cash equivalents and restricted cash | 34,584 |
| Cash, cash equivalents and restricted cash at beginning of period | 34,909 |
| Cash, cash equivalents and restricted cash at end of period | 69,493 |
Alamar Biosciences, Inc. (ALMR)
Alamar Biosciences, Inc. (ALMR)